39 results about "Valvular regurgitation" patented technology

A device, a system and a method for treating heart valve regurgitation. The annulus reshaping device comprises a base and a plurality of legs radially arranged there upon. The device can transform from a delivery configuration wherein it is deliverable by catheter to a treatment site, into a deployment configuration, and then a treatment configuration for treating valvular regurgitation. The device is implanted into the annulus of a heart valve, and the legs of the device can be telescopically withdrawn to apply an inward force to the annulus. The system comprises a device slidably received within a catheter. The method of treatment comprises delivering a device to a treatment area, via catheter, releasing the device from the catheter, positioning the legs of the device on a valve annulus, and applying an inward force to the annulus to reduce the regurgitation.

The invention relates in some aspects to a device for use in the transcatheter treatment of mitral valve regurgitation, including steerable guidewires, implantable coaptation assistance devices, anchoring systems for attaching a ventricular projection of an implantable coaptation device, a kit, and methods of using an implantable coaptation assistance device among other methods.

A device, a system and a method for treating heart valve regurgitation. The annulus reshaping device comprises a base and a plurality of legs radially arranged there upon. The device can transform from a delivery configuration wherein it is deliverable by catheter to a treatment site, into a deployment configuration, and then a treatment configuration for treating valvular regurgitation. The device is implanted into the annulus of a heart valve, and the legs of the device can be telescopically withdrawn to apply an inward force to the annulus. The system comprises a device slidably received within a catheter. The method of treatment comprises delivering a device to a treatment area, via catheter, releasing the device from the catheter, positioning the legs of the device on a valve annulus, and applying an inward force to the annulus to reduce the regurgitation.

The present invention is an apparatus designed to effectuate restoration of normal aortic valvular function where there is aortic valvular regurgitation either primary or secondary to diseases of the aorta such as aortic aneurysm, aortic dissection, rheumatic aortic disease annuloaortic ectasia and etc. is present. The present invention provides an apparatus for repairing aortic annulus composed of (1) a band type inner stabilizer (sometimes ring type inner stabilizer) which is implanted in the true aortic lumen to fix the aortic annular diameter and (2) an outer felt stabilizer which is implanted on the outside surface of aorta to support the inner stabilizer. Furthermore, the present invention provides an apparatus for restoring the sinotubular junction in the ascending aorta which is composed of (1) a ring type inner stabilizer which is implanted in the sinotubular junction in the ascending aorta and (2) an outer felt stabilizer which is implanted on the outside surface of the sinotubular junction to support the inner stabilizer.

A system for treating mitral valve regurgitation includes a tensioning device having a plurality of helical anchors and a tensioning filament. One embodiment of the invention includes a method for attaching a tensioning device to the annulus of a mitral valve in a trans-leaflet configuration, and applying a tension force to the tension filament in order to exert force vectors on the annulus, thereby reshaping the mitral valve annulus so that the coaption of the anterior and posterior leaflets of the mitral is improved during ventricular contraction.

The invention relates to a device for use in the transcatheter treatment of mitral valve regurgitation, specifically a coaptation assistance element for implantation across the valve; a system including the coaptation assistance element and anchors for implantation; a system including the coaptation assistance element and delivery catheter; and a method for transcatheter implantation of a coaptation element across a heart valve.

The invention relates to a device for use in the transcatheter treatment of mitral valve regurgitation, specifically a coaptation assistance element for implantation across the valve; a system including the coaptation assistance element and anchors for implantation; a system including the coaptation assistance element and delivery catheter; and a method for transcatheter implantation of a coaptation element across a heart valve.

The invention relates to a device for use in the transcatheter treatment of mitral valve regurgitation, specifically a coaptation assistance element for implantation across the valve; a system including the coaptation assistance element and anchors for implantation; a system including the coaptation assistance element and delivery catheter; and a method for transcatheter implantation of a coaptation element across a heart valve.

A system for treating valvular regurgitation in a heart valve includes a flexible canopy and an elongated tether including an elastic portion and an inelastic portion. When the system is in a deployed configuration, a proximal end of the flexible canopy is coupled to an annulus of the heart valve and a distal end of the elongated tether is coupled to a ventricle. The flexible canopy is configured to overlay a first native leaflet of the heart valve, and tension on the elongated tether is applied and / or adjusted to prevent the first leaflet from prolapsing, to maximize coaptation of the flexible canopy with a second native leaflet of the heart valve, and to minimize regurgitation of the heart valve.

A system for treating mitral valve regurgitation includes a tensioning device having a plurality of helical anchors and a tensioning filament. One embodiment of the invention includes a method for attaching a tensioning device to the annulus of a mitral valve in a trans-leaflet configuration, and applying a tension force to the tension filament in order to exert force vectors on the annulus, thereby reshaping the mitral valve annulus so that the coaption of the anterior and posterior leaflets of the mitral is improved during ventricular contraction.

The invention relates to a device for use in the transcatheter treatment of mitral valve regurgitation, specifically a coaptation assistance element for implantation across the valve; a system including the coaptation assistance element and anchors for implantation; a system including the coaptation assistance element and delivery catheter; and a method for transcatheter implantation of a coaptation element across a heart valve.

A system comprising an implantable medical device (IMD). The IMD includes an implantable sensor operable to produce an electrical signal representative of mechanical activity of a heart of a subject and a controller circuit coupled to the sensor. The controller circuit includes a wavelet filter module and a valvular regurgitation (VR) calculation module. The wavelet filter module is configured to extract signal energy information from the electrical signal. The energy information includes variation of signal amplitude with frequency and time. The VR calculation module is configured to calculate a measurement of VR for one or more heartbeats using the energy information.

The invention relates to a device for use in the transcatheter treatment of mitral valve regurgitation, specifically a coaptation assistance element for implantation across the valve; a system including the coaptation assistance element and anchors for implantation; a system including the coaptation assistance element and delivery catheter; and a method for transcatheter implantation of a coaptation element across a heart valve.

The invention relates in some aspects to a device for use in the transcatheter treatment of mitral valve regurgitation, including steerable guidewires, implantable coaptation assistance devices, anchoring systems for attaching a ventricular projection of an implantable coaptation device, a kit, and methods of using an implantable coaptation assistance device among other methods.

The invention relates to a device for use in the transcatheter treatment of mitral valve regurgitation, specifically a coaptation assistance element for implantation across the valve; a system including the coaptation assistance element and anchors for implantation; a system including the coaptation assistance element and delivery catheter; and a method for transcatheter implantation of a coaptation element across a heart valve.

The invention discloses an in-vitro performance testing system and testing method of a transcatheter bicuspid valve valved stent, and relates to prostheses capable of being implanted in vivo, in particular to a testing device and testing method applied to heart valve performance testing. The in-vitro performance testing system comprises a valve testing part which is internally provided with the bicuspid valve valved stent, a liquid circulation device and a monitoring device; a first testing part is a heart specimen of which the left ventricular apex is provided with a circulation inlet, and asecond testing part is a section of artificial blood vessel or a section of blood vessel specimen for sewing the tested bicuspid valve valved stent; the liquid testing device is connected with the first testing part to constitute a first testing circulating path for steady flow circulation and a second testing circulating path for simulating the ventricular beat of the human body; the liquid circulation device is connected with the second testing part to constitute a third testing circulating path which is connected with circulation lateral branches, in vitro tests of fluid mechanic performance, support fixing states, valve backflow, perivalvular leakage, and influences on surrounding important organization structures of the bicuspid valve valved stent can be achieved, and a durability experiment of the bicuspid valve valved stent is completed.

The invention relates to a device for use in the transcatheter treatment of mitral valve regurgitation, specifically a coaptation assistance element for implantation across the valve; a system including the coaptation assistance element and anchors for implantation; a system including the coaptation assistance element and delivery catheter; and a method for transcatheter implantation of a coaptation element across a heart valve.

A system comprising an implantable medical device (IMD). The IMD includes an implantable sensor operable to produce an electrical signal representative of mechanical activity of a heart of a subject and a controller circuit coupled to the sensor. The controller circuit includes a wavelet filter module and a valvular regurgitation (VR) calculation module. The wavelet filter module is configured to extract signal energy information from the electrical signal. The energy information includes variation of signal amplitude with frequency and time. The VR calculation module is configured to calculate a measurement of VR for one or more heartbeats using the energy information.

The invention relates in some aspects to a device for use in the transcatheter treatment of mitral valve regurgitation, including steerable guidewires, implantable coaptation assistance devices, anchoring systems for attaching a ventricular projection of an implantable coaptation device, a kit, and methods of using an implantable coaptation assistance device among other methods.

Techniques are provided for use with a pulmonary artery pressure (PAP) monitor having an implantable PAP sensor. In one example, a PAP signal is sensed that is representative of beat-by-beat variations in PAP occurring during individual cardiac cycles of the patient. The PAP monitor detects peaks within the PAP signal corresponding to valvular regurgitation within the heart, then detects mitral regurgitation (MR) based on the peaks. In other examples, the PAP monitor optimizes pacing parameters based on the PAP signal and corresponding electrical cardiac signals. Examples are provided where the PAP monitor is an external system and other examples are provided where the PAP monitor is a component of an implantable cardiac rhythm management device.

The present invention is provides methods and formulations for preventing or ameliorating progression to chronic heart failure subsequent to cardiac stress, including as a consequence of myocardial infarction (MI), coronary artery disease, hypertension, cardiomyopathy, myocarditis, valvular regurgitation, severe lung disease, and / or severe anemia of chronic disease, by administration of one or more rate-limiting precursors to the synthesis of ATP. In one embodiment the ATP precursor is a pentose selected from one or more of ribose, D-ribose, ribulose, xylitol, xylulose, and a 5-carbon precursor of ribose.

An apparatus (10) is provided for treating regurgitation of blood flow through a diseased heart valve. The diseased heart valve includes an annulus, anterior and posterior valve leaflets, and a subvalvular apparatus. The apparatus includes a substantially annular support member (40) and at least one infra - annular support member (42) securely connected thereto. The substantially annular support member has at least a first intermediate portion, a second intermediate portion, and a posterior end portion extending between the first and second intermediate portions. The posterior end portion is dimensioned for attachment to a posterior portion of the annulus of the diseased heart valve. The at least one infra - annular support member is securely connected to the substantially annular support member at a first location. The at least one infra - annular support member is dimensioned to extend below at least one of the posterior and anterior valve leaflets and across or behind at least one subvalvular structure.

The present invention is an apparatus designed to effectuate restoration of normal aortic valvular function where there is aortic valvular regurgitation either primary or secondary to diseases of the aorta such as aortic aneurysm, aortic dissection, rheumatic aortic disease annuloaortic ectasia and etc. is present.The present invention provides an apparatus for repairing aortic annulus composed of (1) a band type inner stabilizer (sometimes ring type inner stabilizer) which is implanted in the true aortic lumen to fix the aortic annular diameter and (2) an outer felt stabilizer which is implanted on the outside surface of aorta to support the inner stabilizer. Furthermore, the present invention provides an apparatus for restoring the sinotubular junction in the ascending aorta which is composed of (1) a ring type inner stabilizer which is implanted in the sinotubular junction in the ascending aorta and (2) an outer felt stabilizer which is implanted on the outside surface of the sinotubular junction to support the inner stabilizer.

Provided herein are methods and formulations for preventing or ameliorating progression to chronic heart failure subsequent to cardiac stress, including as a consequence of myocardial infarction (MI), coronary artery disease, hypertension, cardiomyopathy, myocarditis, valvular regurgitation, severe lung disease, and / or severe anemia of chronic disease, by administration of one or more rate-limiting precursors to the synthesis of ATP. In one embodiment the ATP precursor is a pentose selected from one or more of ribose, D-ribose, ribulose, xylitol, xylulose, and a 5-carbon precursor of ribose.

The invention relates to the field of medical instruments, in particular to a repair device for preventing valve regurgitation. The device comprises: a mounting bracket; and a single anti-regurgitation leaflet prosthesis for replacing the function of a single autologous leaflet, wherein one end of the single anti-regurgitation leaflet prosthesis is fixed on the mounting bracket. The repair device only replaces a single valve leaflet with a problem, the original functions of the remaining part of the autologous valve leaflet are reserved, meanwhile, the shape of an autologous valve ring is not changed, damage to intracardiac tissue is small, meanwhile, the implantation amount of an implant is small, and irritation is small.

The invention concerns the treatment of cardiac hypertrophy by interferon-gamma (IFN-γ). Cardiac hypertrophy may result from a variety of diverse pathologic conditions, including myocardial infarction, hypertension, hypertrophic cardiomyopathy, and valvular regurgitation. The treatment extends to all stages of the progression of cardiac hypertrophy, with or without structural damage of the heart muscle, regardless of the underlying cardiac disorder.

Techniques are provided for use with a pulmonary artery pressure (PAP) monitor having an implantable PAP sensor. In one example, a PAP signal is sensed that is representative of beat-by-beat variations in PAP occurring during individual cardiac cycles of the patient. The PAP monitor detects peaks within the PAP signal corresponding to valvular regurgitation within the heart, then detects mitral regurgitation (MR) based on the peaks. In other examples, the PAP monitor optimizes pacing parameters based on the PAP signal and corresponding electrical cardiac signals. Examples are provided where the PAP monitor is an external system and other examples are provided where the PAP monitor is a component of an implantable cardiac rhythm management device.

A device for treatment of valve regurgitation is described, comprising frameworks (114, 133, 141, 701, 812, 821, 911) and an anchoring unit (132). The anchoring unit (132) is connected to the frameworks (114, 133, 141, 701, 812, 821, 911); the frameworks (114, 133, 141, 701, 812, 821, 911) can be expanded and compressed and have an inflow end (421) and an opposite outflow end (422); valve leaflets (142, 621, 721, 751) capable of opening and closing in blood flow are provided inside the frameworks (114, 133, 141, 701, 812, 821, 911); the anchoring unit (132) can keep the frameworks (114, 133, 141, 701, 812, 821, 911) in an expanded state at the orifice position of a natural heart valve. The device for treatment of valve regurgitation and an implantation method therefor can effectively treat valve regurgitation.